Citigroup’s Translate Bio, Inc. Common Stock TBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-236,139
| Closed | -$6.5M | – | 6526 |
|
|
2021
Q2 | $6.5M | Buy |
236,139
+46,687
| +25% | +$917K | ﹤0.01% | 1701 |
|
|
2021
Q1 | $3.12M | Buy |
189,452
+164,412
| +657% | +$3.75M | ﹤0.01% | 2169 |
|
|
2020
Q4 | $461K | Buy |
25,040
+13,157
| +111% | +$235K | ﹤0.01% | 4277 |
|
|
2020
Q3 | $162K | Sell |
11,883
-54,018
| -82% | -$833K | ﹤0.01% | 4770 |
|
|
2020
Q2 | $1.18M | Buy |
65,901
+49,095
| +292% | +$740K | ﹤0.01% | 3380 |
|
|
2020
Q1 | $168K | Buy |
16,806
+4,740
| +39% | +$38.8K | ﹤0.01% | 4882 |
|
|
2019
Q4 | $98K | Sell |
12,066
-829,370
| -99% | -$7.65M | ﹤0.01% | 5792 |
|
|
2019
Q3 | $8.34M | Buy |
841,436
+831,724
| +8,564% | +$7.85M | 0.01% | 1533 |
|
|
2019
Q2 | $122K | Buy |
9,712
+1,144
| +13% | +$12.1K | ﹤0.01% | 5690 |
|
|
2019
Q1 | $87K | Buy |
8,568
+6,899
| +413% | +$52.9K | ﹤0.01% | 5887 |
|
|
2018
Q4 | $12K | Sell |
1,669
-1,072
| -39% | -$7.85K | ﹤0.01% | 7101 |
|
|
2018
Q3 | $27K | Sell |
2,741
-568,259
| -100% | -$6.62M | ﹤0.01% | 6948 |
|
|
2018
Q2 | $7.22M | Buy |
+571,000
| New | +$6.9M | 0.01% | 1521 |
|
Citigroup's TBIO Position: Q3 2021 in Review
Citigroup sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 236,139 shares — an estimated $6.5M sold.
Citigroup first reported a position in TBIO in Q2 2018 and held it in 13 quarters. The position peaked at $8.34M in Q3 2019. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.
- Citigroup reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
- Citigroup sold 236,139 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $6.5M.
- Citigroup first reported a position in Translate Bio, Inc. Common Stock in Q2 2018 and held it in 13 quarters.
- Citigroup's Translate Bio, Inc. Common Stock position peaked at $8.34M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.
Based on Citigroup's 13F filing for Q3 2021, filed 10 Nov 2021.